Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director · See Remarks | August 24, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 488,182 |
Reported balance
After 2026-08-24 transaction · row 1
1 source rowRow 1 · 2026-08-24 · Sale · Disposed 13,818 · Balance 488,182 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2021 Filed Sep 3, 2021 23:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 21,145 | $177.72 | $3,757,830.19 |
DisclosureSEC source: 0001209191-21-054899 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,331 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $177.14 to $178.13. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,530 | $176.65 | $1,330,155.68 |
DisclosureSEC source: 0001209191-21-054899 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,476 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $176.14 to $177.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,728 | $175.69 | $479,292.41 |
DisclosureSEC source: 0001209191-21-054899 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,006 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $175.14 to $176.135. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,049 | $174.39 | $182,934.59 |
DisclosureSEC source: 0001209191-21-054899 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,734 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $174.14 to $175.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 23:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 41,666 | $5.04 | $209,996.64 |
DisclosureSEC source: 0001209191-21-054899 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 337 | $161.85 | $54,542.61 |
DisclosureSEC source: 0001209191-21-053391 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,117 F1 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 30,552 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · derivative · entry 12 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,448 Underlying: Class A Common Stock · 30,552 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · derivative.exercise_date: This option, originally for 175,000 shares, of which 30,552 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 11,114 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · derivative · entry 11 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,968 Underlying: Class A Common Stock · 11,114 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: This option, originally for 200,000 shares, of which 140,032 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $184.95 | $73,981.00 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · nonDerivative · entry 10 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,454 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $184.84 to $184.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $184.02 | $147,219.52 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · nonDerivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,854 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $183.66 to $184.595. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,800 | $183.02 | $329,440.68 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · nonDerivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,654 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $182.63 to $183.485. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,200 | $181.98 | $946,300.16 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,454 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $181.63 to $182.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,800 | $181.13 | $1,593,960.72 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,654 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $180.63 to $181.625. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 10,713 | $180.13 | $1,929,776.61 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,454 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $179.63 to $180.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,050 | $179.08 | $1,441,595.61 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,167 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $178.63 to $179.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,903 | $178.25 | $1,052,191.45 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,217 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $177.63 to $178.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 30,552 | $5.04 | $153,982.08 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 11,114 | $1.20 | $13,336.80 |
DisclosureSEC source: 0001209191-21-049643 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 41,666 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-21-045469 · doc4.xml · derivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,082 Underlying: Class A Common Stock · 41,666 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · derivative.exercise_date: This option, originally for 200,000 shares, of which 128,918 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,200 | $195.60 | $234,721.56 |
DisclosureSEC source: 0001209191-21-045469 · doc4.xml · nonDerivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,454 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $195.23 to $196.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,500 | $194.58 | $486,445.75 |
DisclosureSEC source: 0001209191-21-045469 · doc4.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,654 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $194.17 to $195.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,989 | $193.63 | $1,159,622.52 |
DisclosureSEC source: 0001209191-21-045469 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,154 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $193.15 to $194.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,872 | $192.69 | $553,416.88 |
DisclosureSEC source: 0001209191-21-045469 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,143 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $192.14 to $193.085. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,202 | $191.58 | $1,379,741.88 |
DisclosureSEC source: 0001209191-21-045469 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,015 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $191.14 to $192.105. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 12,845 | $190.51 | $2,447,149.76 |
DisclosureSEC source: 0001209191-21-045469 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,217 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $190.14 to $191.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 9,058 | $189.80 | $1,719,202.97 |
DisclosureSEC source: 0001209191-21-045469 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,062 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $189.14 to $190.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 41,666 | $1.20 | $49,999.20 |
DisclosureSEC source: 0001209191-21-045469 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 41,666 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-21-037900 · doc4.xml · derivative · entry 11 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,748 Underlying: Class A Common Stock · 41,666 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · derivative.exercise_date: This option, originally for 200,000 shares, of which 87,252 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $180.07 | $180,068.00 |
DisclosureSEC source: 0001209191-21-037900 · doc4.xml · nonDerivative · entry 10 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,454 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · price: This transaction was executed in multiple trades at prices ranging from $179.84 to $180.67. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $179.33 | $197,259.48 |
DisclosureSEC source: 0001209191-21-037900 · doc4.xml · nonDerivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,454 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $178.69 to $179.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 900 | $177.99 | $160,188.03 |
DisclosureSEC source: 0001209191-21-037900 · doc4.xml · nonDerivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,554 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $177.62 to $178.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,350 | $176.18 | $590,204.68 |
DisclosureSEC source: 0001209191-21-037900 · doc4.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,454 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $175.99 to $176.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 13,326 | $175.49 | $2,338,595.73 |
DisclosureSEC source: 0001209191-21-037900 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,804 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $174.96 to $175.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,433 | $174.47 | $1,122,372.59 |
DisclosureSEC source: 0001209191-21-037900 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,130 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $173.94 to $174.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,473 | $173.44 | $602,345.66 |
DisclosureSEC source: 0001209191-21-037900 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,563 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $172.94 to $173.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,792 | $172.35 | $653,562.96 |
DisclosureSEC source: 0001209191-21-037900 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,036 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $171.94 to $172.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,292 | $171.54 | $1,422,406.36 |
DisclosureSEC source: 0001209191-21-037900 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,828 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $170.93 to $171.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:49 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 41,666 | $1.20 | $49,999.20 |
DisclosureSEC source: 0001209191-21-037900 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 24, 2021 Filed May 27, 2021 00:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 351 | $162.66 | $57,093.52 |
DisclosureSEC source: 0001209191-21-036101 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,454 F3 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of RSUs. F4 · balance_after: The number of shares beneficially owned following the reported transaction is as of May 24, 2021. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,586 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · derivative · entry 12 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,414 Underlying: Class A Common Stock · 17,586 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · derivative.exercise_date: This option, originally for 200,000 shares, of which 45,586 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 24,080 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · derivative · entry 11 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,952 Underlying: Class A Common Stock · 24,080 shares Expires 2026-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $197.91 | $118,746.00 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · nonDerivative · entry 10 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,636 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $197.55 to $198.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $194.88 | $97,439.00 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · nonDerivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,236 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $194.76 to $195.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $193.97 | $155,173.92 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · nonDerivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,736 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $193.75 to $194.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,361 | $192.96 | $1,034,433.36 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,536 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $192.59 to $193.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 20,100 | $192.10 | $3,861,274.32 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,897 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $191.57 to $192.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,905 | $191.07 | $1,510,393.33 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,997 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $190.57 to $191.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,908 | $190.19 | $933,449.58 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,902 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $189.57 to $190.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,492 | $189.07 | $282,097.21 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,810 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $188.51 to $189.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,586 | $1.20 | $21,103.20 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.